Obducat secures financing for more than 12 months

The successful rights issue means that the company has secured financing for more than 12 months ahead. The capital will be invested in expanded customer outreach and an increase in the pace of product development. It also provides a liquidity buffer that is necessary for a planned listing of the company on Nasdaq/OMX.
In a previous interview with BioStock, Patrik Lundström, CEO of Obducat, was asked what new and existing shareholders can look forward to in the next 12 months.
- They can look forward to significantly increased order intake, increased sales, the launch of a new production platform for large-area applications such as the production of displays, and a listing of the company on Nasdaq/OMX.
BioStock has previously done an analysis of Obducat which you can find here.
 
The text is written by BioStock's editorial team. The content of Biostock's news and analyses is independent, but Biostock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.